Amgen’s Weight-Loss Drug Candidate Shows Promise in Early Data

Phase I data for Amgen’s experimental weight-loss drug MariTide suggest the candidate may produce longer-lasting effects than popular glucagon-like peptide-1 medicines currently on the market such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, according to results published Monday in the journal Nature Metabolism.